Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06276738 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease

StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Mar 30, 2024 to Jun 30, 2024v3
  2. Study description revisedv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluate LINFU® in patients who exhibit signs or symptoms (i.e. jaundice, abdominal pain, weight loss, nausea and vomiting etc.) suggestive of pancreatic cancer (PDAC) or have evidence of imaging studies suggestive of PDAC.
Trial Details
NCT Number NCT06276738
Lead Sponsor Adenocyte, LLC
Conditions
(from sponsor)		 Pancreatic Cancer, Jaundice, Abdominal Neoplasm
Related terms Abdominal Neoplasms, Jaundice, Pancreatic Neoplasms
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov